NetworkNewsWire
Editorial Coverage: More than 700 million
people worldwide are affected with some form of mental illness,
addiction or eating disorder, representing about 13% of total
disease burden. In reality, the worldwide picture is a bit murky,
considering the high frequency of nondiagnosis as well as lack of
treatment, even in the most developed countries. Advances in
medicine to treat these conditions of the brain have been elusive,
as conventional drugs that treat symptoms and not underlying causes
remain the most popular. There are reasons to be optimistic about
the future, though, underscored by increased research activity
surrounding psychedelics. This is the area of focus for
Cybin Inc. (NEO: CYBN) (Profile), which this
week acquired Adelia
Therapeutics, a transformational move that broadened
addressable indications in its pipeline and strengthened its
scientific team. Cybin has a three-pillar approach, its
initial sights set on treating major depression disorder ("MDD")
now expanded to address additional indication as well through
innovative psychedelic therapeutics development and unique delivery
technologies. Cybin stands shoulder-to-shoulder with peers striving
for a world of better mental well-being such as COMPASS
Pathways Plc (NASDAQ: CMPS), Mind Medicine
Inc (OTC: MMEDF) (NEO: MMED), Numinus Wellness
Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI) and
HAVN
Life Sciences (OTC: HAVLF), all of which are
developing innovative approaches to bring new psychedelic-based
therapies to patients in need.
- Mental health disorders forecast to cost $16 trillion by
2030.
- Cybin’s acquisition of Adelia Therapeutics accelerates growth
strategy, bolsters world-class scientific team, increases IP
portfolio to seven patent filings.
- The company executes on three-pillar growth plan focused on
developing psychedelic-based drug discovery platform, efficient
drug-delivery methods, novel treatment regimens.
Click here to view
the custom infographic of the Cybin editorial.
Time for Effective Options to Alleviate Pain, Financial
Strain
More than 700 million people dealing with illnesses takes a toll
on health-care systems. By 2030, it is estimated that the aggregate
cost of mental health maladies to the global economy could reach a
stunning $16
trillion. The problem is not that there aren’t options to treat
a disease such as depression; there are many,
including selective serotonin reuptake inhibitors ("SSRI") such as
Prozac (fluoxetine), and serotonin and norepinephrine reuptake
inhibitors ("SNRI") such as Effexor XR (venlafaxine).
In fact, more than 40
million Americans take antidepressants or some other type of
psychiatric drug. No, the problem is not availability. The problem
lies more in conventional drugs often being accompanied by negative side
effects and doing more to mask the disease rather than get to
the root of the condition.
Meeting Promises
Toronto-based Cybin Inc. (NEO:
CYBN) is developing technologies and delivery systems, aiming
to improve bioavailability to potentially achieve the desired
medicinal effects of psychedelics at low-dosage levels. In its
latest move, the company acquired Adelia Therapeutics. The
acquisition combines two talented management and scientific teams
while also bringing an attractive intellectual property portfolio
of seven patent filings with further IP development and expanding
Cybin’s focus beyond treatment of MDD to include multiple
indications.
“We are thrilled to join forces with Adelia, as we see this
transaction as potentially advancing Cybin’s ability to innovate
our psychedelic drug development program and diversify beyond major
depressive disorder,” said Cybin CEO Doug Drysdale. “Adelia’s focus
on creating novel therapeutics, including novel delivery methods
and innovative therapeutic regimens can support our goal of
creating therapies that result in faster onset of action, smoother
pharmacokinetic profiles, shorter treatment durations, and reduced
side effects. Leveraging Adelia’s expertise across multiple
molecules and multiple indications could potentially allow Cybin to
extend its reach and capability to address gaps across a larger
domain.”
“Cybin is committed to expansion through strategic M&A
opportunities,” he continued. “Today we deliver on that commitment
and we will continue to pursue such opportunities to drive growth
in the future.”
The acquisition dovetails perfectly with Cybin’s already stated
drug-delivery goals, bringing onboard a proprietary drug-delivery
platform developed by Adelia for the controlled administration of
psychedelic therapies that bypass the problems with conventional
administration and liver metabolism.
This move reinforces Cybin’s focus on R&D of next-generation
medications based on psilocybin, a nonhabit forming, naturally
occurring psychedelic compound found in certain species of
so-called “magic” mushrooms, for the treatment of MDD. Clinical
studies at Johns Hopkins revealed that psilocybin, given with
supportive psychotherapy, produced rapid and large reductions in
depressive symptoms, with most participants showing improvement and
half of study participants actually achieving remission through a
four-week follow-up.
Impressive Team Additions
Cybin intends to be a leader in this exciting breakthrough for
mental health. In its efforts, the company has assembled an
experienced team with a combined 80-plus years in the
pharmaceutical industry that recently raised C$45 million in the
largest go-public capital raise in the Canadian psychedelic sector
and total of C$55 million raised across Seed, Series-A and Series-B
financing rounds. Part of that capital is now being deployed in a
powerful move to acquire Adelia Therapeutics Inc., further
bolstering the fundamental strengths of Cybin.
While raising capital, Cybin shared it three-pillar plan of
building a novel drug-discovery platform, developing optimal
technology and novel treatment regimens. The IP model is
multipronged, covering chemically synthesized molecules, delivery
mechanisms, screeners, protocols and new drug formulations
alongside a merger and acquisition strategy to acquire proprietary
technologies and novel compounds and molecules. Cybin also holds
worldwide exclusive rights to sublingual film delivery technology
from Intelgenx for the delivery of psilocybin and other psychedelic
molecules.
The leadership team joining Cybin is impressive, including
co-founder and CEO Alex Nivorozhkin, PhD and co-founder, and
president and chief strategy officer Brett J. Greene, both of whom
bring decades of experience in psychedelics and drug development
and are affiliated with Northeastern University’s world-renowned
Center for Drug Discovery in Boston. COO Michael Palfreyman, PhD,
DSc., is an accomplished pharmaceutical industry veteran
responsible for more than 30 successful clinical programs.
Members of the Adelia team have CV’s steeped in success, such as
35 successful exits, work developing proprietary ketamine analogs,
experience with major pharmas (e.g., Johnson&Johnson, Pfizer,
Roche), a wealth of highly cited peer-reviewed publications, and
oversight in the R&D and commercialization of drugs such as
Allegra (fexofenadine), Sabril (vigabatrin), Anzemet (dolasetron),
and Vaniqa (eflornithine). The team further brings a Rolodex of
major network affiliations, including the likes of Massachusetts
Institute of Technology, Harvard, Stanford, Yale and Northeastern
University.
An Operating Facility Too
With the acquisition, Cybin is significantly broadening its
footprint in the United States. In addition to the reach and
esteemed networks of Adelia’s leadership team, the company is also
gaining an operating development facility in the epicenter of
Boston biotech, a heartbeat of innovation in the country.
“Cybin brings complementary resources to the table, and together
we can advance our shared goal of bringing psychedelic therapies
across a broad spectrum of indications,” commented Nivorozhkin, who
will assume the role of Cybin chief scientific officer upon
completion of the acquisition. “[We] look forward to the
opportunity to transform the psychedelic therapeutics industry
together,” he said.
A Movement Underway
The world is seeing a resurgence in interest in psychedelics
after a relative standstill that lasted several decades. Only older
generations recall a growing body of evidence supporting the
therapeutic advantages of psychedelics before 1970. To the demise
of the emerging health-care segment, President Richard Nixon signed
the Controlled Substances Act into law that year, outlawing
psychedelics as Schedule I drugs with no medicinal benefits.
Small amounts of research in specific academic pockets have been
completed over the years, but the acceleration in lab and clinical
work has been tied to the legalization of cannabis amid public
outcries for new medical options in recent years. Finally, the
negative stigma is abating and lawmakers at state and local levels
are taking the initiative to open the door to developing new
therapies. Following the pioneering lead of Denver, Colorado, three
other major U.S. cities have legalized psychedelics in the last
year, along with the state of Oregon.
COMPASS
Pathways Plc (NASDAQ: CMPS) has effectively served as
a tide that has elevated the entire psychedelics space, earning
attention from institutions and retail traders alike with a
high-profile initial public offering in September and spectacular
ascension in
value since. From its headquarters in the United Kingdom,
COMPASS is regarded by most as the gold standard in psychedelics
because it is in mid-stage clinical trials evaluating its synthetic
version of psilocybin for use in treatment-resistant depression.
The company is developing its psilocybin program for the indication
under a Breakthrough Therapy designation from the FDA.
Much like COMPASS, Mind Medicine
Inc (OTC: MMEDF) (NEO: MMED) embodies the
attention psychedelics are getting, enabling the raising of capital
to support large leadership and
advisory teams, which includes Bruce Linton, a co-founder and
former CEO of Canopy Growth Corp., the largest cannabis company in
the world. MindMed is developing several experimental therapies in
its pipeline derived from psychedelics without the hallucination
effect. The flagship product in 18-MC, which the company is
developing to treat the cause of the brain disease that is
addiction rather than merely substituting one addictive substance
for another less harmful one.
Numinus Wellness
Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI) is
bringing a diversified
approach to the industry to create a mental health company with
a complete ecosystem for making psychedelic-assisted psychotherapy
available to people in need. Numinus is integrated, with a Health
Canada-licensed laboratory for research and analytics services
(Numinus Bioscience), a unit (Numinus R&D) for developing new
psychedelic-assisted therapeutic protocols and a third division
(Numiness Health) that provides treatments to patients through
clinical and virtual services. The company can trumpet many
first-mover advantages, including being the first company in Canada
to receive a license to grow and extract psilocybin from mushrooms,
for which the first
harvest was recently completed.
HAVN
Life Sciences (OTC: HAVLF) is an active part of the
Canadian biotech community, researching the benefits of microdosing
a variety of psychedelics for hard-to-treat conditions while
pursuing standardized extraction of psychoactive compounds under a
research license from Health Canada. There is a feel-good component
to the HAVN mission in that it works with veterans and military
thought leaders in its quest to initiate clinical trials addressing
post-traumatic stress disorder ("PTSD") and other trauma related
ailments. A Memorandum of
Understanding was inked this month for the purpose of HAVN
supplying the international veterans organization Heroic Hearts
Project for collaboration on future clinical studies planned to
evaluate low doses of ayahuasca, psilocybin and ketamine in mental
trauma patients.
The world is witnessing a genuine progression into the
opportunity psychedelics present to make a meaningful impact on an
area of health care that is ripe for innovation. This movement is
quietly being spearheaded by seasoned and successful
drug-development veterans and supported by the investment
community, providing some real reason for optimism about potential
breakthroughs to bridge some large unattended gaps in mental
health.
For more information about Cybin Inc., please visit Cybin Inc. (NEO:
CYBN)
About NetworkNewsWire
NetworkNewsWire
(“NNW”) is a financial news and content distribution company, one
of 40+ brands within the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via InvestorWire to
reach all target markets, industries and demographics in the most
effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a full
array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Havn Life Sciences (CE) (USOTC:HAVLF)
Historical Stock Chart
From Jan 2025 to Feb 2025
Havn Life Sciences (CE) (USOTC:HAVLF)
Historical Stock Chart
From Feb 2024 to Feb 2025
